Skip to main content

Research Repository

Advanced Search

A genome-wide association study provides evidence of sex-specific involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) with diabetic neuropathic pain.

Meng, Weihua; Deshmukh, Harshal A.; Donnelly, Louise A.; Wellcome Trust Case Control Consortium 2 (WTCCC2); Surrogate Markers For Micro- And Macro-Vascular Hard Endpoints For Innovative Diabetes Tools (SUMMIT) Study Group; Torrance, Nicola; Colhoun, Helen M.; Palmer, Colin N.A.; Smith, Blair H.

Authors

Weihua Meng

Harshal A. Deshmukh

Louise A. Donnelly

Wellcome Trust Case Control Consortium 2 (WTCCC2)

Surrogate Markers For Micro- And Macro-Vascular Hard Endpoints For Innovative Diabetes Tools (SUMMIT) Study Group

Nicola Torrance

Helen M. Colhoun

Colin N.A. Palmer

Blair H. Smith



Abstract

Neuropathic pain is defined as pain arising as a direct consequence of a lesion or a disease affecting the somatosensory system and it affects around 1 in 4 diabetic patients in the UK. The purpose of this genome-wide association study (GWAS) was to identify genetic contributors to this disorder. Cases of neuropathic pain were defined as diabetic patients with a multiple prescription history of at least one of five drugs specifically indicated for the treatment of neuropathic pain. Controls were diabetic individuals who were not prescribed any of these drugs, nor amitriptyline, carbamazepine, or nortriptyline. Overall, 961 diabetic neuropathic pain cases and 3260 diabetic controls in the Genetics of Diabetes Audit and Research Tayside (GoDARTS) cohort were identified. We found a cluster in the Chr1p35.1 (ZSCAN20-TLR12P) with a lowest P value of 2.74 × 10-7 at rs71647933 in females and a cluster in the Chr8p23.1, next to HMGB1P46 with a lowest P value of 8.02×10-7 at rs6986153 in males. Sex-specific narrow sense heritability was higher in males (30.0%) than in females (14.7%). This GWAS on diabetic neuropathic pain provides evidence for the sex-specific involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) with the disorder, indicating the need for further research.

Citation

MENG, W., DESHMUKH, H.A., DONNELLY, L.A., WELLCOME TRUST CASE CONTROL CONSORTIUM 2 (WTCCC2), SURROGATE MARKERS FOR MICRO- AND MACRO-VASCULAR HARD ENDPOINTS FOR INNOVATIVE DIABETES TOOLS (SUMMIT) STUDY GROUP, TORRANCE, N., COLHOUN, H.M., PALMER, C.N.A. and SMITH, B.H. 2015. A genome-wide association study provides evidence of sex-specific involvement of Chr1p35.1 (ZSCAN20-TLR12P) and Chr8p23.1 (HMGB1P46) with diabetic neuropathic pain. EBioMedicine [online], 2(10), pages 1386-1393. Available from: https://doi.org/10.1016/j.ebiom.2015.08.001

Journal Article Type Article
Acceptance Date Aug 1, 2015
Online Publication Date Aug 4, 2015
Publication Date Oct 31, 2015
Deposit Date Feb 6, 2020
Publicly Available Date Feb 6, 2020
Journal EBioMedicine
Electronic ISSN 2352-3964
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 2
Issue 10
Pages 1386-1393
DOI https://doi.org/10.1016/j.ebiom.2015.08.001
Keywords Neuropathic pain; GWAS; Heritability; Sex-specific
Public URL https://rgu-repository.worktribe.com/output/819947